What TRIAD Is Testing — and Why It Matters
The Test of Rapamycin in Aging Dogs is asking whether a drug that acts on a fundamental aging pathway can change how dogs age. Here is what the trial is actually measuring, and what researchers hope it will demonstrate.
A trial about aging itself
TRIAD — the Test of Rapamycin in Aging Dogs — is a research program connected to the broader [Dog Aging Project](https://dogagingproject.org/triad). It asks a question that, until recently, science rarely asked directly: can we influence the biological processes of aging itself, rather than only treating the diseases that aging produces?
> Pawformance Labs is not affiliated with, sponsored by, endorsed by, or in contact with TRIAD, the Dog Aging Project, or their research teams. We did not conduct this research. We cannot enroll a dog, provide rapamycin, or speak on their behalf. Everything here is our own independent, informational summary of publicly available research. Nothing on this page is a suggestion to obtain or give any drug to a dog.
What rapamycin does
Rapamycin is a small-molecule drug that acts on a nutrient-sensing pathway called mTOR. This pathway acts as a kind of cellular switch: when nutrients are abundant, mTOR promotes growth; when nutrients are scarce — or when rapamycin is present — the pathway shifts toward maintenance and repair.
In laboratory animals across multiple species, inhibiting mTOR has been associated with extended lifespan and delayed age-related decline. That pattern is part of what made researchers want to ask the same question in dogs.
What the trial measures
Rather than looking at a single biomarker, TRIAD follows companion dogs over time and measures a range of outcomes:
- Heart function — how the heart changes with age and whether that trajectory can be influenced
- Activity and mobility — whether dogs stay more capable for longer
- Cognitive measures — whether mental sharpness is preserved
- Body composition — muscle and lean mass, not just weight
- Survival — the hardest endpoint: lifespan itself
This breadth matters. A drug that moves one lab value but does not change how a dog actually lives has not answered the question owners care about.
What researchers hope to learn
The potential benefits TRIAD is designed to detect are significant:
- Whether aging processes in dogs respond to intervention at all
- Whether heart function can be preserved or improved over time
- Whether activity and mobility decline more slowly
- Whether cognitive aging can be influenced
- Whether lifespan itself can be extended
Any of these would be a landmark result. But results are not yet published, and hope is not evidence.
Why companion dogs make this possible
Dogs age faster than humans, so a study can follow a meaningful portion of a life within a research timeframe. They also share our environment — homes, food, air, daily routine — which makes findings more relevant to real-world aging than laboratory animal studies alone.
What this is not
TRIAD is a controlled research trial with protocols, oversight and endpoints. It is not a product, a prescription, or something an owner can replicate at home. Rapamycin is a drug with known effects and risks, and it is being studied in a specific research context.
We follow this work because the question matters. We describe what it finds rather than what we hope it finds.
Keep going